Genomic ancestry as a predictor of haemodynamic profile in heart failure

Carregando...
Imagem de Miniatura
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Citação
OPEN HEART, v.3, n.2, article ID UNSP e000434, 9p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: The aim of this study is to assess the association between genetic ancestry, self-declared race and haemodynamic parameters in patients with chronic heart failure (HF). Methods: Observational, cross-sectional study. Eligible participants were aged between 18 and 80 years; ejection fraction was <= 50%. Patients underwent genetic analysis of ancestry informative markers, echocardiography and impedance cardiography (ICG). Race was determined by self-classification into two groups: white and non-white. Genomic ancestry was estimated using a panel of 101 348 polymorphic markers and three continental reference populations (European, African and Native American). Results: Our study included 362 patients with HF between August 2012 and August 2014. 123 patients with HF declared themselves as white and 234 patients declared themselves as non-white. No statistically significant differences were found regarding the ICG parameters according to self-declared race. The Amerindian ancestry was positively correlated with systolic time ratio (r=0.109, p<0.05). The thoracic fluid content index (r=0.124. p<0.05), E wave peak (r=0.127. p<0.05) and E/e' ratio (r=0.197. p<0.01) were correlated positively with African ancestry. In multiple linear regression, African ancestry remained associated with the E/e0 ratio, even after adjustment to risk factors. Conclusions: The African genetic ancestry was associated with worse parameters of diastolic function; the Amerindian ancestry correlated with a worse pattern of ventricular contractility, while self-declared colour was not helpful to infer haemodynamic profiles in HF.
Palavras-chave
Referências
  1. Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109
  2. ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037
  3. Alexander M, 1999, AM HEART J, V137, P919, DOI 10.1016/S0002-8703(99)70417-5
  4. Bernardez-Pereira S, 2014, BMC CARDIOVASC DISOR, V14, DOI [10.1186/1471-2261-14-32, 10.1186/1471-2261-14-90]
  5. Cardena MMSG, 2014, INT J CARDIOL, V176, P527, DOI 10.1016/j.ijcard.2014.07.039
  6. Cardena MMSG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062005
  7. Castellanos LR, 2009, J CARD FAIL, V15, P41, DOI 10.1016/j.cardfail.2008.09.003
  8. Charron P, 2001, EUR J PHARMACOL, V417, P1, DOI 10.1016/S0014-2999(01)00878-0
  9. Feldman MW, 2003, NATURE, V424, P374, DOI 10.1038/424374a
  10. Flack JM, 2011, AM J CARDIOVASC DRUG, V11, P83, DOI 10.2165/11586930-000000000-00000
  11. Gheorghiade M, 2013, J AM COLL CARDIOL, V61, P391, DOI 10.1016/j.jacc.2012.09.038
  12. Ginsburg GS, 2007, J AM COLL CARDIOL, V50, P930, DOI 10.1016/j.jacc.2007.05.025
  13. Harjai KJ, 2002, CLIN CARDIOL, V25, P479, DOI 10.1002/clc.4960251008
  14. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  15. Hebbar S, 1999, NEW ENGL J MED, V341, P288
  16. *IBGE, CENS DEM 2000 CAR GE
  17. Joffe Samuel W, 2013, J Clin Med Res, V5, P194, DOI 10.4021/jocmr1376w
  18. Kehdy FSG, 2015, P NATL ACAD SCI USA, V112, P8696, DOI 10.1073/pnas.1504447112
  19. Kurnik D, 2008, PHARMACOGENET GENOM, V18, P895, DOI 10.1097/FPC.0b013e328309733f
  20. Lima-Costa MF, 2015, SCI REP-UK, V5, DOI 10.1038/srep09812
  21. Nazroo JY, 2003, AM J PUBLIC HEALTH, V93, P277, DOI 10.2105/AJPH.93.2.277
  22. Parrott Charles W, 2004, Congest Heart Fail, V10, P11, DOI 10.1111/j.1527-5299.2004.03407.x
  23. Pena SDJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017063
  24. Pereira SB, 2013, MOL MED REP, V7, P259, DOI 10.3892/mmr.2012.1120
  25. Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
  26. Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P2517, DOI 10.1001/jama.289.19.2517
  27. Russo C, 2010, AM HEART J, V160, P152, DOI 10.1016/j.ahj.2010.04.010
  28. Sharp A, 2008, J AM COLL CARDIOL, V52, P1015
  29. SHG C, HUMAN GENOME DIVERSI
  30. Taylor MR, 2014, JACC-HEART FAIL, V2, P561, DOI 10.1016/j.jchf.2014.06.010
  31. Thompson Brenda, 2008, Congest Heart Fail, V14, P261, DOI 10.1111/j.1751-7133.2008.00001.x
  32. Xie HG, 2001, PHARMACOGENETICS, V11, P191, DOI 10.1097/00008571-200104000-00002
  33. Yancy CW, 2001, NEW ENGL J MED, V344, P1358, DOI 10.1056/NEJM200105033441803